secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-01-05T23:59:59+00:00
Accession:  0001564590-22-000348
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi announces interim analysis for Phase 2 CANAL trial in Q1 2022, ends PRISM enrollment Jan 31
--------------------------------------------------------------------------------

- Phase 2 CANAL trial of Haduvio for chronic cough in IPF: interim statistical update planned Q1 2022 based on conditional power.
- Top-line data from CANAL expected H1 2022; interim may allow proof-of-concept before full enrollment.
- Phase 2b/3 PRISM trial for prurigo nodularis: enrollment ends Jan 31, 2022; top-line data H1 2022.
- Top-line data from both trials expected in first half of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022000348/0001564590-22-000348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022000348/trvi-8k_20220105.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-000348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer